Hematology

The CGTLive™ Hematology specialty topic page houses the most up-to-date clinical news coverage in the field of hematology gene and cell therapy. It also includes video interviews with key opinion leaders in the field of hematology/oncology about the latest relevant FDA actions, clinical guideline updates, and clinical trial findings related to the development of cell therapies, gene therapies, and engineered and regenerative medicines for various blood disorders.

Latest News

Françoise Bernaudin, MD, the head of the Referral Center for Sickle Cell Disease and Clinical Research Department at Hôpital Intercommunal de Créteil of the Université Paris-Est
10-Year Data Show Allogeneic Stem Cell Transplant Benefits for Sickle Cell Anemia

December 10th 2024

A long-term follow-up to the DREPAGREFFE-1 trial suggest that children with sickle cell anemia may benefit long-term on risk of cerebral injury, cognitive functions, and quality of life over standard care transfusions.

Timothy S. Fenske, MD, MS
Autologous HCT Shows No Benefit for Patients With MCL in First Complete Remission

December 10th 2024

Susan Bal, MD, University of Alabama at Birmingham
Arlo-Cel Generates Excitement, Moves Quickly to Phase 3 Studies for Multiple Myeloma

December 10th 2024

Novartis's CAR-T Tisagenlecleucel Continues to Show Efficacy for R/R Follicular Lymphoma in Long-Term Follow-Up
Novartis's CAR-T Tisagenlecleucel Continues to Show Efficacy for R/R Follicular Lymphoma in Long-Term Follow-Up

December 10th 2024

Allogeneic CAR-NK Therapy TAK-007 Achieves Responses in R/R B-NHL
Allogeneic CAR-NK Therapy TAK-007 Achieves Responses in R/R B-NHL

December 9th 2024

Latest CME Events & Activities

Navigating the Next Wave in BTK Inhibition Strategies: Maximizing Clinical Benefit in CLL and MCL, What’s Next...

December 14, 2024

Register Now!

Focusing on Key Updates on the Outlook of Acute Lymphocytic Leukemia (ALL) Management

View More

Oncology Town Hall™: Primary Investigators Present Key Abstracts in CLL from San Diego

View More

Understanding the Recent Developments in Myelodysplastic Syndromes (MDS)

View More

Experts Address the Hottest Topics in AML: Considerations on FLT3, IDH1/2, TP53, Maintenance, Novel Combinations and Beyond!

View More

Medical Crossfire®: Novel BTKi Strategies Transforming Aggressive and Indolent B-Cell Malignancies

View More

The Effect of Recent Updates on the Outlook of Acute Myeloid Leukemia (AML) Management

View More

The Latest Advancements in the Treatment of Chronic Myeloid Leukemia (CML)

View More

Medical Crossfire®: Bridging Expert Guidance and Evidence-Based Recommendations in the Treatment of AYA and Adult ALL

View More

Medical Crossfire®: Novel BTKi Strategies Transforming Aggressive and Indolent B-Cell Malignancies

View More

How We Do It®: Novel Biologic Strategies Reshaping Treatment Decision-Making in Pediatric to Adult Hodgkin Lymphoma

View More

Experts Address the Hottest Topics in AML: Considerations on FLT3, IDH1/2, TP53, Maintenance, Novel Combinations and Beyond!

View More

Real-World Applications of Asparaginase Formulations in ALL and LBL From Pediatric/AYA to Adult Treatment: Maximizing Clinical Benefits Through Multidisciplinary Care

View More

How Do We Treat GVHD Today…And Tomorrow? Treatment Algorithms for Key Decision Points in Prophylaxis Care, Acute, and Chronic Disease

View More

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

View More

Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat

View More

Real-World Applications of Asparaginase Formulations in ALL and LBL From Pediatric/AYA to Adult Treatment: Maximizing Clinical Benefits Through Multidisciplinary Care

View More

Medical Crossfire®: Bridging Expert Guidance and Evidence-Based Recommendations in the Treatment of AYA and Adult ALL

View More

Putting Your Stamp on the Next Generation of Care in CML — Improving Outcomes from Frontline to R/R Treatment Settings

View More

Show Me the Data: How Do We Navigate the Latest Evidence on Novel Therapies and Trials Across GvHD Prophylaxis, Acute, and Chronic Care?

View More

Medical Crossfire®: Bridging Evidence to Practice in AML…Updates on FLT3, IDH1/2, Maintenance, Combos, and Clinical Trials

View More

How We Do It®: New Combinations Reshaping Treatment Decision-Making in Newly Diagnosed Multiple Myeloma

View More

Show Me the Data™: Pushing CAR Ts Forward Across Lymphoid Malignancies…Accelerating Access in the Community and the Treatment Strategies for the Road Ahead

View More

Medical Crossfire®: Bridging Expert Guidance and Evidence-Based Recommendations in the Ever-Evolving Treatment of MF, PV, and ET

View More

Medical Crossfire®: New Horizons in Acute Lymphoblastic Leukemia—How The Experts Apply New Evidence from AYA to Adult Scenarios

View More

From Barriers to Breakthroughs in Multiple Myeloma: How Trials Compare to the Real-World Management of Patients in Your Practice

View More

Pediatric-Inspired Asparaginase Regimens for Patients With Acute Lymphocytic Leukemia

View More

29th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma

February 27 - March 2, 2025

Register Now!

The Impact of CAR T-Cell Therapy on Hematological Malignancies

View More

Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions

View More

More News

© 2024 MJH Life Sciences

All rights reserved.